Optimizing Medication Treatment of Opioid Use Disorder During COVID-19 (SARS-CoV-2).
Where this comes from
- Record sourced from PubMed, PMID 32412931.
- Also identified by DOI 10.1097/ADM.0000000000000678 and PMC identifier 7273937.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
: The COVID-19 health crisis joined, rather than supplanted, the opioid crisis as the most acutely pressing threats to US public health. In the setting of COVID-19, opioid use disorder treatment paradigms are being disrupted, including the fact that methadone clinics are scrambling to give "take-home" doses where they would typically not. The rapid transition away from in-person examination, dosing and group therapy in an era of social isolation calls for adjustments to clinical practice, including emphasizing patient-provider communication, favoring new inductees on buprenorphine and leveraging technology to optimize safety of medication treatment.
Medical subject headings
- Coronavirus Infections
- Infection Control
- Narcotic Antagonists
- Opiate Substitution Treatment
- Opioid-Related Disorders
- Pandemics
- Pneumonia, Viral
- Substance Abuse Treatment Centers